• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Thinking more about therapy with convalescent plasma for COVID-19 patients.

作者信息

Han Guangshu, Zhou Yi-Hua

机构信息

Department of Internal Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School , Nanjing, Jiangsu, China.

Departments of Laboratory Medicine and Infectious Diseases, Nanjing Drum Tower Hospital and Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School , Nanjing, Jiangsu, China.

出版信息

Hum Vaccin Immunother. 2020 Nov 1;16(11):2601-2603. doi: 10.1080/21645515.2020.1787073. Epub 2020 Jul 9.

DOI:10.1080/21645515.2020.1787073
PMID:32643512
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7734059/
Abstract
摘要

相似文献

1
Thinking more about therapy with convalescent plasma for COVID-19 patients.更多地思考针对新冠病毒肺炎患者使用康复期血浆进行治疗的问题。
Hum Vaccin Immunother. 2020 Nov 1;16(11):2601-2603. doi: 10.1080/21645515.2020.1787073. Epub 2020 Jul 9.
2
Antibodies, epicenter of SARS-CoV-2 immunology.抗体，新冠病毒免疫学的核心
Cell Death Differ. 2021 Feb;28(2):821-824. doi: 10.1038/s41418-020-00711-w. Epub 2021 Jan 26.
3
Management of COVID-19 Virus Infection by Convalescent Plasma.恢复期血浆治疗新型冠状病毒肺炎病毒感染
Iran J Allergy Asthma Immunol. 2020 May 17;19(S1):3-6. doi: 10.18502/ijaai.v19i(s1.r1).2847.
4
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
5
Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience.快速成功实施 COVID-19 恢复期血浆计划——南非经验。
Viruses. 2021 Oct 12;13(10):2050. doi: 10.3390/v13102050.
6
Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.恢复期血浆治疗 SARS-CoV-2 相关急性呼吸窘迫综合征的儿科患者。
Pediatr Blood Cancer. 2020 Nov;67(11):e28693. doi: 10.1002/pbc.28693. Epub 2020 Sep 4.
7
Perspectives for immune plasma treatment of COVID-19.COVID-19 的免疫血浆治疗展望。
Turk J Med Sci. 2021 Feb 26;51(1):1-9. doi: 10.3906/sag-2005-410.
8
Challenges of Convalescent Plasma Therapy on COVID-19.恢复期血浆疗法治疗新冠病毒肺炎面临的挑战
J Clin Virol. 2020 Jun;127:104358. doi: 10.1016/j.jcv.2020.104358. Epub 2020 Apr 10.
9
Neutralizing monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的中和单克隆抗体。
Nat Rev Immunol. 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x. Epub 2021 Apr 19.
10
Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.病例报告：双滤过血浆置换获得的抗 SARS-CoV-2 恢复期抗体的作用。
Front Immunol. 2021 Jun 30;12:711915. doi: 10.3389/fimmu.2021.711915. eCollection 2021.

引用本文的文献

1
Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.恢复期血浆用于 COVID-19 的预防和治疗：系统评价和定量分析。
JMIR Public Health Surveill. 2021 Apr 7;7(4):e25500. doi: 10.2196/25500.

本文引用的文献

1
Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019.新冠肺炎患者恢复期血浆疗法对病毒脱落和生存的影响。
J Infect Dis. 2020 Jun 16;222(1):38-43. doi: 10.1093/infdis/jiaa228.
2
Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.6名新冠肺炎康复者恢复期血浆中的抗SARS-CoV-2病毒抗体水平。
Aging (Albany NY). 2020 Apr 22;12(8):6536-6542. doi: 10.18632/aging.103102.
3
Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.中国武汉 COVID-19 患者恢复期血浆治疗。
J Med Virol. 2020 Oct;92(10):1890-1901. doi: 10.1002/jmv.25882. Epub 2020 Jun 29.
4
Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea.韩国两名急性呼吸窘迫综合征 COVID-19 患者使用恢复期血浆疗法。
J Korean Med Sci. 2020 Apr 13;35(14):e149. doi: 10.3346/jkms.2020.35.e149.
5
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.恢复期血浆疗法治疗重症 COVID-19 患者的疗效。
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
6
Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.恢复期血浆治疗严重急性呼吸综合征冠状病毒 2 感染的危重症患者。
Chest. 2020 Jul;158(1):e9-e13. doi: 10.1016/j.chest.2020.03.039. Epub 2020 Mar 31.
7
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
8
Covid-19: FDA approves use of convalescent plasma to treat critically ill patients.新冠疫情：美国食品药品监督管理局批准使用康复期血浆治疗重症患者。
BMJ. 2020 Mar 26;368:m1256. doi: 10.1136/bmj.m1256.
9
Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).分析早期体液免疫反应以诊断新型冠状病毒病（COVID-19）。
Clin Infect Dis. 2020 Jul 28;71(15):778-785. doi: 10.1093/cid/ciaa310.
10
A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus.巨细胞病毒免疫球蛋白预防先天性巨细胞病毒感染的随机试验。
N Engl J Med. 2014 Apr 3;370(14):1316-26. doi: 10.1056/NEJMoa1310214.